NCT06437223: An ongoing trial by Inflammx Therapeutics Inc
This trial is ongoing. It must report results 4 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06437223 |
|---|---|
| Title | A Phase 2 Study to Compare the Efficacy and Safety of Orally Administered Xiflam™ Therapy With Orally Administered Placebo in Patients With Ocular and Systemic Manifestations of Post COVID Sequelae Known as "Long" COVID |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 12, 2024 |
| Completion date | Sept. 30, 2025 |
| Required reporting date | Sept. 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 19, 2026 |
| Days late | None |